hVIVO, a specialty biopharma company with clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases.
hVIVO changed its name from Retroscreen Virology in April 2015. The business is a plc quoted on the AIM London Stock Exchange (ticker ‘HVO’).
Leveraging human disease models in flu, RSV, and asthma exacerbation, the hVIVO platform captures ‘disease in motion’, illuminating the entire disease life cycle from healthy to sick and back to health. Via this insight, the platform enables the rational selection of drug targets and biomarkers while simultaneously providing a revolutionary methodology for testing product safety and efficacy. The Company has three clinical stage products currently in development as well as a growing pre-clinical pipeline.
This video provides an insight into the state of the art medical and clinical quarantine facilities at hVIVO in London, UK.
hVIVO recruits volunteers in the UK to take part in their clinical studies using the ‘FluCamp’ brand.
hVIVO is a plc quoted on the AIM London Stock Exchange (ticker ‘HVO’).
The excerpt video below, as broadcast on UK national television, provides additional insight into the valuable work that hVIVO conducts to help accelerate better treatments, faster.
Drug & Biomarker Discovery
By mapping the right biological targets and biomarkers, the hVIVO platform accelerates and de-risks product discovery. In the last two years alone, hVIVO’s disruptive ”pathomics” approach to get at the root cause of disease has reduced the drug pre-discovery timeline by 90% and produced the first-ever map of the human host response to flu, allowing hVIVO to identify the pathophysiology behind flu infections in order to produce targeted products and therapies. Through pathomics, drug targets to prevent, treat, and aide recovery are revealed, along with the biomarkers to simplify drug development, as well as the causal biology that can be developed into ground-breaking predictor and patient stratification tools. hVIVO’ s strategy is to exhaustively mine its flu data for discoveries, the first of which is expected in 2016. Sample collection has begun to next map asthma using this pioneering pathomics approach.
Clinical Product Testing
By identifying the promising products, the hVIVO platform accelerates drug development and reduces costs and risks. As market leader, hVIVO has pioneered the use of human disease models for early stage clinical testing with over 45 trials in over 2,200 subjects, for a wide range of industry, government, and academic clients and collaborators. Market adoption of this disruptive methodology by industry and regulators has progressed quickly with nearly $2 billion in exit events underpinned by hVIVO data since 2010 alone. hVIVO’ s ‘human in a lab’ approach generates a disease state in which to test the safety and efficacy of products in a controlled and tailored setting. Because the infections are generated with wild-type viruses, hVIVO provides a way to test with lab-like precision in humans before investing time and money in less-controlled field based studies, thus minimising the risk of later stage failures. In addition to providing services to strategically important customers, hVIVO uses the platform to test products born out of its equity investments, and will in due course use the platform to test its proprietary inventions from pathomics. In 2015 and 2016, hVIVO completed two such investments in PrEP Biopharm and Imutex, acquiring several clinical assets for universal flu, panviral flu prophylaxys, and mosquito-borne diseases, and is already actively leveraging our platform to test these assets and accelerate their development.
hVIVO was originally incorporated in 1988 as Retroscreen Virology (the name was changed to hVIVO in 2015). The company was spun-out from Queen Mary, University of London, to commercialise the academic research of Professor John Oxford in the field of retroviruses, which at the time, were considered to have promise in the fight against HIV/Aids.
In 2001, Professor Oxford was asked to expand from the laboratory and leverage his early career experience in these early human viral challenge studies. Studies were conducted at hVIVO, led by Dr Robert Lambkin-Williams and Dr Anthony Gilbert, to develop a series of well-characterised virus stocks and human disease models whilst demonstrating that utilising these in human viral challenge studies provided clients a faster and cost effective route to market for their therapeutics. One notable study was the first proof of the efficacy of a siRNA therapeutic, in which hVIVO’s human disease model and challenge study results proved instrumental.
With hVIVO human disease models gaining acceptance in an increasing number of peer-reviewed publications, hVIVO designed and built its own dedicated, bespoke quarantine unit in London, which opened in early 2011 and we continue to make rapid progress. In 2015 and 2016 alone, hVIVO generated the first host response map of flu and reduced pre-discovery by 90%. Over this time the company’s scientific and medical depth and expertise has developed substantially, with expansion into respiratory diseases such as asthma, novel discovery research with our pathomics efforts and collaborations with partners such as the US National Institutes of Health (NIH).
Our scientific experts, medical team and all of our staff are committed to leveraging their significant experience in drug discovery and development to deliver an exceptional experience for our volunteers, designing and conducting challenge studies to address critical questions and developing new human models of disease in areas of unmet medical need to revolutionise drug development and deliver better treatments, faster.
‘hVIVO’ and ‘FluCamp’ are registered trademarks of hVIVO Services Limited.